ClinicalTrials.gg
RecruitingNCT07271693Updated Nov 16, 2026

A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7806881 in Healthy Participants

A Phase 1 interventional study of RO7806881 and Placebo in Healthy Volunteers, sponsored by Hoffmann-La Roche. Recruiting at 1 site in New Zealand. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2025; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
128
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

The main purpose of this study is to evaluate the safety and tolerability of single and multiple ascending doses of RO7806881 in healthy participants.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.

Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be males or females who are overtly healthy as determined by medical evaluation
  • Participants must have body weight (BW) ≥ 40 kilograms (kg) (not applicable to Cohort A9) and (BMI) within the range 18-32 kilograms per square meter (kg/m\^2) (inclusive)

Inclusion Criteria Specific to Cohort A9 (East Asian Cohort):

  • Must be of ethnic Chinese, Korean, or Japanese origin
  • Must have a BW >35 kg and BMI within the range 18-32 kg/m2 (inclusive)

Exclusion criteria

Exclusion Criteria:

  • Pregnancy, breastfeeding, or intention to become pregnant during the study or within 6 months after the final dose of study treatment
  • History of any , gastrointestinal, renal, hepatic, pulmonary, neurological, psychiatric, cardiovascular, endocrinological, hematological, or allergic disease; metabolic disorder; cancer or cirrhosis
  • Latent tuberculosis (TB) or potentially active TB
  • Any major illness within 1 month before the screening examination or any febrile illness within 1 week prior to the screening visit and up to first dose administration
  • Concomitant disease or condition that could interfere with, or treatment of which might interfere with, the conduct of the study, or that would, in the opinion of the Investigator, pose an unacceptable risk to the participant in this study
  • History of to biologic agents or any of the in the formulation, or other allergy that contraindicates participation in the study
  • within 1 month of the first screening visit or during the screening period
  • Non-live vaccines within 2 weeks prior to dosing
  • Previous exposure to RO7806881
  • Positive virus (HCV) antibody test result
  • Positive test results for infection
  • Positive (HIV) antibody test result
  • Positive test result consistent with cytomegalovirus (CMV) or Epstein-Barr virus (EBV)
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
128 participants (estimated)

Study arms

  • Experimental
    RO7806881: Single Ascending Dose (SAD)

    Participants will receive single doses of RO7806881, at 8 dose levels across 9 different cohorts (A1-A9) including one optional SAD cohort of East Asian participants (Cohort A9).

    Drug: RO7806881

  • Placebo comparator
    Placebo: SAD

    Participants will receive single doses of placebo, matched to each of the 8 dose levels of RO7806881.

    Drug: Placebo

  • Experimental
    RO7806881: Multiple Ascending Doses (MAD)

    Participants will receive multiple doses of RO7806881, at 4 dose levels across 4 different cohorts (B1-B4), per the predefined dosing regimen.

    Drug: RO7806881

  • Placebo comparator
    Placebo: MAD

    Participants will receive multiple doses of placebo, matched to each of the 4 dose levels of RO7806881, per the predefined dosing regimen.

    Drug: Placebo

Interventions

  • DrugRO7806881

    RO7806881 will be administered as per the schedule specified in the protocol.

  • DrugPlacebo

    Placebo will be administered as per the schedule specified in the protocol.

06

What researchers measure

Primary outcomes

  1. SAD Part: Number of Participants With Adverse Events (AEs)

    Time frame: Up to Day 127

  2. MAD Part: Number of Participants With AEs

    Time frame: Up to Day 162

  3. SAD Part: Number of Participants With Dose-limiting Adverse Events (DLAEs)

    Time frame: Up to Day 127

  4. MAD Part: Number of Participants With DLAEs

    Time frame: Up to Day 162

Secondary outcomes

  1. SAD and MAD Parts: Serum Concentration of RO7806881

    Time frame: SAD: Up to Day 127; MAD: Up to Day 162

  2. SAD and MAD Parts: Maximum Concentration (Cmax) of RO7806881

    Time frame: SAD: Up to Day 127; MAD: Up to Day 162

  3. SAD and MAD Parts: Minimum Concentration (Cmin) of RO7806881

    Time frame: SAD: Up to Day 127; MAD: Up to Day 162

  4. SAD and MAD Parts: Area Under the Curve (AUC) From the Last Time of Dosing to the Last Measurable Concentration (AUClast) of RO7806881

    Time frame: SAD: Up to Day 127; MAD: Up to Day 162

  5. SAD and MAD Parts: Apparent Total Body Clearance (CL/F) of RO7806881

    Time frame: SAD: Up to Day 127; MAD: Up to Day 162

  6. SAD and MAD Parts: Volume of Distribution at Steady-state Conditions (Vss) of RO7806881

    Time frame: SAD: Up to Day 127; MAD: Up to Day 162

  7. SAD and MAD Parts: Dose Proportionality for AUC

    Time frame: SAD: Up to Day 127; MAD: Up to Day 162

  8. SAD and MAD Parts: Dose Proportionality for Cmax

    Time frame: SAD: Up to Day 127; MAD: Up to Day 162

  9. MAD Part: Accumulation Ratio (Racc) of RO7806881

    Time frame: Up to Day 162

  10. SAD and MAD Parts: Absolute Bioavailability of RO7806881

    Time frame: SAD: Up to Day 127; MAD: Up to Day 162

07

Study locations

1 of 1 sites recruiting
08

References and documents

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2025 (actual). Primary completion is estimated for May 2027, 16 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2025
First posted
Dec 9, 2025
StartActual
Dec 22, 2025
Primary completionEst.
May 11, 2027
CompletionEst.
May 11, 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
2 updates, last Nov 16, 2026
Show all 2 updates
  1. Nov 16, 2026
    Minor edits only
    + 1 other change: verification date
  2. Oct 19, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07271693
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Dec 9, 2025
Start date
Dec 22, 2025
Primary completion
May 11, 2027 (estimated)
Completion
May 11, 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

Reference Study ID Number: BP46089 https://forpatients.roche.com/ No attachments to email below.
Contact
global-roche-genentech-trials@gene.com
888-662-6728
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Contact
Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion